🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Ocular Therapeutix clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA register with Ocular Therapeutix as lead sponsor. Synced 26 Sep 2026
4Current trials
2Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Ocular Therapeutix is the lead sponsor of 4 current clinical trials in our USA register. 2 are recruiting patients now. All registered phases are Phase 3. The drugs named most often in its trials are Otx-Tki and Aflibercept. The most-studied condition is Neovascular Age-Related Macular Degeneration.

ClinicalTrials.gov trials by status

  • Recruiting250%
  • Active, closed250%

Trials by phase

  • Phase 34100%
01

Clinical trials sponsored by Ocular Therapeutix

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
NCT07235085 · ClinicalTrials.gov ↗ · Non-Proliferative Diabetic Retinopathy
Phase 3 Recruiting 2025-11 USA
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
NCT07516132 · ClinicalTrials.gov ↗ · Neovascular Age-Related Macular Degeneration (nAMD)
Drug: Otx-Tki
Phase 3 Recruiting 2026-04 USA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
NCT06223958 · Neovascular Age-Related Macular Degeneration
Phase 3 Active, closed 2024-01 USA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918 · ClinicalTrials.gov ↗ · Neovascular Age-related Macular Degeneration
Phase 3 Active, closed 2024-11 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Ocular Therapeutix trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Ocular Therapeutix trials

4 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA42

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Neovascular Age-Related Macular Degeneration

SponsorTrials
Adverum Biotechnologies2
Innostellar Biotherapeutics2

Sponsors with the most current trials registered for this condition.

06

Questions about Ocular Therapeutix trials

How many clinical trials does Ocular Therapeutix sponsor?

Ocular Therapeutix is the lead sponsor of 4 current trials on ClinicalTrials.gov in our USA register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Ocular Therapeutix trials recruiting?

Yes. 2 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Ocular Therapeutix testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Otx-Tki (3) and Aflibercept (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.